Comerica Bank Lowers Holdings in LeMaitre Vascular, Inc. $LMAT

Key Points

• Comerica Bank trimmed its stake in LeMaitre Vascular by 6.7% in Q4, selling 9,589 shares and ending the period with 133,243 shares worth about $10.8 million (0.59% of the company).
• LeMaitre beat Q4 estimates with $0.68 EPS (vs. $0.67 expected) and $64.45M in revenue (vs. $62.98M), reported revenue growth of 15.7% YoY, and set FY2026 EPS guidance of 2.810–3.010 (consensus ~2.89).
• The company raised its quarterly dividend to $0.25 (annualized $1.00, ~0.9% yield), even as insiders have been net sellers — 215,438 shares sold (~$23.06M) over the past 90 days, with insiders owning 9.5% of shares.

Comerica Bank trimmed its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 6.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 133,243 shares of the medical instruments supplier's stock after selling 9,589 shares during the quarter. Comerica Bank owned 0.59% of LeMaitre Vascular worth $10,806,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Cornerstone Planning Group LLC lifted its holdings in shares of LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 283 shares during the period. MAI Capital Management purchased a new stake in shares of LeMaitre Vascular in the 3rd quarter worth $38,000. First Horizon Corp purchased a new stake in shares of LeMaitre Vascular in the 3rd quarter worth $39,000. Geneos Wealth Management Inc. lifted its holdings in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 398 shares during the period. Finally, EverSource Wealth Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the 2nd quarter worth $47,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Trading Down 1.9%

Shares of NASDAQ LMAT opened at $112.40 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. The stock has a market capitalization of $2.57 billion, a P/E ratio of 44.78, a price-to-earnings-growth ratio of 3.30 and a beta of 0.67. LeMaitre Vascular, Inc. has a 1-year low of $78.01 and a 1-year high of $118.01. The business has a fifty day moving average price of $108.21 and a 200 day moving average price of $93.68.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.01. The firm had revenue of $64.45 million during the quarter, compared to analysts' expectations of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm's quarterly revenue was up 15.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Equities research analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.20. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular's dividend payout ratio (DPR) is 39.84%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares in the company, valued at approximately $736,406.33. This trade represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director David B. Roberts sold 8,464 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the sale, the director owned 17,979 shares of the company's stock, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 215,438 shares of company stock worth $23,062,911. 9.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Freedom Capital upgraded LeMaitre Vascular to a "hold" rating in a report on Tuesday, March 31st. Barrington Research upped their target price on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Wells Fargo & Company upped their price objective on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 26th. Zacks Research upgraded LeMaitre Vascular from a "hold" rating to a "strong-buy" rating in a research note on Monday, April 13th. Finally, Weiss Ratings upgraded LeMaitre Vascular from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $105.80.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.